The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile
Open accessAbstract
Introduction: Levels of Alzheimer's disease (AD)‐related proteins in plasma neuronal derived exosomes (NDEs) were quantified to identify biomarkers for prediction and staging of mild cognitive impairment (MCI) and AD. Methods: Plasma exosomes were extracted, precipitated, and enriched for neuronal source by anti‐L1CAM antibody absorption. NDEs were characterized by size (Nanosight) and shape (TEM) and extracted NDE protein biomarkers were quantified by ELISAs. Plasma NDE cargo was injected into normal mice, and results were characterized by immunohistochemistry to determine pathogenic potential. Results: Plasma NDE levels of P‐T181‐tau, P‐S396‐tau, and Aβ1–42 were significantly higher, whereas those of neurogranin (NRGN) and the repressor element 1‐silencing transcription factor (REST) were significantly lower in AD and MCI converting to AD (ADC) patients compared to cognitively normal controls (CNC) subjects and stable MCI patients. Mice injected with plasma NDEs from ADC patients displayed increased P‐tau (PHF‐1 antibody)–positive cells in the CA1 region of the hippocampus compared to plasma NDEs from CNC and stable MCI patients. Conclusions: Abnormal plasma NDE levels of P‐tau, Aβ1–42, NRGN, and REST accurately predict conversion of MCI to AD dementia. Plasma NDEs from demented patients seeded tau aggregation and induced AD‐like neuropathology in normal mouse CNS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids
Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0322s30 · Cited by 5,766
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Self-citationAlzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Exosomes – vesicular carriers for intercellular communication
Simons, M., & Raposo, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.03.007 · Cited by 2,351
Alzheimer’s disease β-amyloid peptides are released in association with exosomes
Rajendran, L., Honsho, M., Zahn, T. R., Keller, P., Geiger, K. D., Verkade, P., & Simons, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603838103 · Cited by 1,343
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
The glucose oxidase-DAB-nickel method in peroxidase histochemistry of the nervous system
Shu, S., Ju, G., & Fan, L. (1988) · Neuroscience Letters · doi:10.1016/0304-3940(88)90346-1 · Cited by 1,227
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048
Self-citationCells release prions in association with exosomes
Fevrier, B., Vilette, D., Archer, F., Loew, D., Faigle, W., Vidal, M., Laude, H., & Raposo, G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308413101 · Cited by 997
Grundman, M. (2004) · Archives of Neurology · doi:10.1001/archneur.61.1.59 · Cited by 972
REST: A mammalian silencer protein that restricts sodium channel gene expression to neurons
Chong, J. A., Tapia-Ramirez, J., Kim, S., Toledo-Aral, J. J., Zheng, Y., Boutros, M. C., Altshuller, Y. M., Frohman, M. A., Kraner, S. D., & Mandel, G. (1995) · Cell · doi:10.1016/0092-8674(95)90298-8 · Cited by 967
Fiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.008 · Cited by 959
Self-citationvan der Pol, E., Coumans, F. A. W., Grootemaat, A. E., Gardiner, C., Sargent, I. L., Harrison, P., Sturk, A., van Leeuwen, T. G., & Nieuwland, R. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12602 · Cited by 917
REST and stress resistance in ageing and Alzheimer’s disease
Lu, T., Aron, L., Zullo, J., Pan, Y., Kim, H., Chen, Y., Yang, T.-H., Kim, H.-M., Drake, D., Liu, X. S., et al. (2014) · Nature · doi:10.1038/nature13163 · Cited by 772
Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission
Alvarez-Erviti, L., Seow, Y., Schapira, A. H., Gardiner, C., Sargent, I. L., Wood, M. J. A., & Cooper, J. M. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.01.029 · Cited by 748
Extracellular vesicles round off communication in the nervous system
Budnik, V., Ruiz-Cañada, C., & Wendler, F. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.29 · Cited by 712
Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease
Shi, M., Liu, C., Cook, T. J., Bullock, K. M., Zhao, Y., Ginghina, C., Li, Y., Aro, P., Dator, R., He, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1314-y · Cited by 676
Self-citationEarly Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain
Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley–Whyte, E. T., Frosch, M. P., Albert, M. S., Hyman, B. T., & Irizarry, M. C. (2004) · Neurology · doi:10.1212/01.wnl.0000115115.98960.37 · Cited by 666
Mild cognitive impairment: Disparity of incidence and prevalence estimates
Ward, A., Arrighi, H. M., Michels, S., & Cedarbaum, J. M. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.01.002 · Cited by 569
Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease
Goetzl, E. J., Boxer, A., Schwartz, J. B., Abner, E. L., Petersen, R. C., Miller, B. L., & Kapogiannis, D. (2015) · Neurology · doi:10.1212/wnl.0000000000001702 · Cited by 446
Self-citationKapogiannis, D., Boxer, A., Schwartz, J. B., Abner, E. L., Biragyn, A., Masharani, U., Frassetto, L., Petersen, R. C., Miller, B. L., & Goetzl, E. J. (2015) · The FASEB Journal · doi:10.1096/fj.14-262048 · Cited by 345
Self-citationKvartsberg, H., Duits, F. H., Ingelsson, M., Andreasen, N., Öhrfelt, A., Andersson, K., Brinkmalm, G., Lannfelt, L., Minthon, L., Hansson, O., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.009 · Cited by 340
Innovative diagnostic tools for early detection of Alzheimer's disease
Laske, C., Sohrabi, H. R., Frost, S. M., López-de-Ipiña, K., Garrard, P., Buscema, M., Dauwels, J., Soekadar, S. R., Mueller, S., Linnemann, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.004 · Cited by 316
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease
Portelius, E., Zetterberg, H., Skillbäck, T., Törnqvist, U., Andreasson, U., Trojanowski, J. Q., Weiner, M. W., Shaw, L. M., & Mattsson, N. (2015) · Brain · doi:10.1093/brain/awv267 · Cited by 279
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease
Kester, M. I., Teunissen, C. E., Crimmins, D. L., Herries, E. M., Ladenson, J. H., Scheltens, P., van der Flier, W. M., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1867 · Cited by 246
Fluid biomarkers in Alzheimer’s disease – current concepts
Rosén, C., Hansson, O., Blennow, K., & Zetterberg, H. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-20 · Cited by 214
Low neural exosomal levels of cellular survival factors in Alzheimer's disease
Goetzl, E. J., Boxer, A., Schwartz, J. B., Abner, E. L., Petersen, R. C., Miller, B. L., Carlson, O. D., Mustapic, M., & Kapogiannis, D. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.211 · Cited by 208
Self-citationVingtdeux, V., Hamdane, M., Loyens, A., Gelé, P., Drobeck, H., Bégard, S., Galas, M.-C., Delacourte, A., Beauvillain, J.-C., Buée, L., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609475200 · Cited by 195
Neurochemical Dissection of Synaptic Pathology in Alzheimer's Disease
Davidsson, P., & Blennow, K. (1998) · International Psychogeriatrics · doi:10.1017/s1041610298005110 · Cited by 182
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
Parnetti, L., Farotti, L., Eusebi, P., Chiasserini, D., De Carlo, C., Giannandrea, D., Salvadori, N., Lisetti, V., Tambasco, N., Rossi, A., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00053 · Cited by 176
Tau PET Imaging in Alzheimer’s Disease
Okamura, N., Harada, R., Furumoto, S., Arai, H., Yanai, K., & Kudo, Y. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0500-6 · Cited by 168
Transcriptional Regulation: Cancer, Neurons and the REST
Coulson, J. M. (2005) · Current Biology · doi:10.1016/j.cub.2005.08.032 · Cited by 168
van Rossum, I. A., Vos, S. J. B., Handels, R. L. H., & Visser, P. J. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091606 · Cited by 158
Stern, R. A., Tripodis, Y., Baugh, C. M., Fritts, N. G., Martin, B. M., Chaisson, C., Cantu, R. C., Joyce, J. A., Shah, S., Ikezu, T., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-151028 · Cited by 155
Soares, H. D., Chen, Y., Sabbagh, M. N., Rohrer, A., Schrijvers, E. M. C., & Breteler, M. M. B. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05066.x · Cited by 121
Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
Mattsson, N., Insel, P. S., Landau, S. M., Jagust, W., Donohue, M., Shaw, L. M. J., Trojanowski, J. Q., Zetterberg, H., Blennow, K., Weiner, M. W., et al. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.81 · Cited by 116
Aging enhances release of exosomal cytokine mRNAs by Aβ 1‐42 ‐stimulated macrophages
Mitsuhashi, M., Taub, D. D., Kapogiannis, D., Eitan, E., Zukley, L. M., Mattson, M. P., Ferrucci, L., Schwartz, J. B., & Goetzl, E. J. (2013) · The FASEB Journal · doi:10.1096/fj.13-238980 · Cited by 70
Self-citationChang, J. W., SCHUMACHER, E., Coulter, P. M., Vinters, H. V., & Watson, J. B. (1997) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199710000-00004 · Cited by 63
Grad, L. I., Pokrishevsky, E., Silverman, J. M., & Cashman, N. R. (2014) · Prion · doi:10.4161/19336896.2014.983398 · Cited by 63
Campbell, S. N., Zhang, C., Monte, L., Roe, A. D., Rice, K. C., Taché, Y., Masliah, E., & Rissman, R. A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141281 · Cited by 56
Self-citationTau is reduced in AD plasma and validation of employed ELISA methods.
Sparks, D. L., Kryscio, R. J., Sabbagh, M. N., Ziolkowski, C. H. J., Lin, Y., Sparks, L. M., Liebsack, C., & Johnson‐Traver, S. (2012) · Europe PMC (PubMed Central) · Cited by 55
Transmission Electron Microscopy
Burghardt, R. C., & Droleskey, R. E. (2006) · Current Protocols in Microbiology · doi:10.1002/9780471729259.mc02b01s03 · Cited by 55
CSF biomarkers for Alzheimer’s pathology and the effect size of APOE ɛ4
Andréasson, U., Lautner, R., Schott, J. M., Mattsson, N., Hansson, O., Herukka, S.-K., Helisalmi, S., Ewers, M., Hampel, H. J., Wallin, A., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.18 · Cited by 34
Cerebrospinal fluid biomarkers in cardiac arrest survivors
Rosén, C., Rosén, H., Andréasson, U., Bremell, D., Bremler, R., Hagberg, L., Rosengren, L., Blennow, K., & Zetterberg, H. (2013) · Resuscitation · doi:10.1016/j.resuscitation.2013.10.032 · Cited by 32
Lanari, A., & Parnetti, L. (2009) · The Scientific World JOURNAL · doi:10.1100/tsw.2009.106 · Cited by 31
Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease
Rosén, C., & Zetterberg, H. (2013) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32835f6747 · Cited by 27
Zetterberg, H., Lautner, R., Skillbäck, T. B., Rosén, C., Shahim, P., Mattsson, N., & Blennow, K. (2014) · Advances in clinical chemistry · doi:10.1016/b978-0-12-800141-7.00005-x · Cited by 25
Diagnostic Utility of CSF Tau and Aβ42 in Dementia: A Meta‐Analysis
Agarwal, R., & Tripathi, C. B. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/503293 · Cited by 19
Cited by
A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Targeting and Crossing the Blood-Brain Barrier with Extracellular Vesicles
Saint-Pol, J., Gosselet, F., Duban-Deweer, S., Pottiez, G., & Karamanos, Y. (2020) · Cells · doi:10.3390/cells9040851 · Cited by 503
Mustapic, M., Eitan, E., Werner, J. K., Berkowitz, S. T., Lazaropoulos, M. P., Tran, J., Goetzl, E. J., & Kapogiannis, D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00278 · Cited by 441
Self-citationHigh complement levels in astrocyte‐derived exosomes of Alzheimer disease
Goetzl, E. J., Schwartz, J. B., Abner, E. L., Jicha, G. A., & Kapogiannis, D. (2018) · Annals of Neurology · doi:10.1002/ana.25172 · Cited by 370
Self-citation
Metadata
- Authors
- Winston, C. N., Goetzl, E. J., Akers, J. C., Carter, B. S., Rockenstein, E. M., Galasko, D., Masliah, E., & Rissman, R. A.
- Venue
- Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Publisher
- Wiley
- Published
- 2016-01
- Volume
- 3
- Issue
- 1
- Pages
- 63-72
- ISSN
- 2352-8729 (ISSN-L)
- OpenAlex
- W2352124481
- Cited by
- 379
- References
- 48
- FWCI
- 20.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.